$0.258
-0.010 (-3.77%)收盤時
MDCX 同業比較
In the context of the broader market, MDCX competes directly with industry leaders such as PLUR and ADVB. With a market capitalization of $17.70M, it holds a leading position in the sector. When comparing efficiency, MDCX's gross margin of N/A stands against PLUR's 33.53% and ADVB's N/A. Such benchmarking helps identify whether Medicus Pharma Ltd is trading at a premium or discount relative to its financial performance.
Medicus Pharma Ltd 財務表現
Medicus Pharma has reported consistent net losses, with a net income of -11,684,427 USD in Q2 2026 and a negative EPS of -0.21. This indicates ongoing financial distress and lack of profitability.
Financials
FY2026Q2
YoY:
+90.80%
-11.48M
Operating Profit
FY2026Q2
YoY:
+89.19%
-11.68M
Net Income after Tax
FY2026Q2
YoY:
-51.16%
-0.21
EPS - Diluted
FY2025Q4
-6.61M
Free Cash Flow
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。